{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of confidence interval are not reached due to censoring rate","groupId":"OG000","lowerLimit":"10.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"OS is defined as the duration from treatment start date to the date of death from any cause. Subjects who are alive or lost to follow up at the time of the analysis will be censored at the last known date they were alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction (4 28-day cycles):\n\nCarfilzomib (IV) @ 20 mg/m\\^2, Day 1 of Cycle 1; @ 56 mg/m\\^2, Day 8,15 of Cycle 1; @ 56 mg/m\\^2, Day 1,8,15 of Cycles 2-4\n\nLenalidomide (Oral) @ 25 mg, once daily at bedtime on Days 1-21 of each cycle (Cycles 1-4)\n\nDexamethasone @ 28 mg orally OR 8 mg IV, once weekly on Day 1,8,15,22 of Cycles 1-2; @28 mg orally OR 8 mg IV on Day 1 of Cycles 3-4\n\nElotuzumab (IV) @ 10 mg/kg, once weekly on Day 1,8,15,22 of Cycles 1-2; @ 20 mg/kg on Day 1 of Cycles 3-4\n\nMaintenance (28-day cycles):\n\nElotuzumab (IV) @ 20 mg/kg, Day 1 of each cycle (Cycles 1-n)\n\nLenalidomide (Oral) @ 15 mg (or last tolerated dose if \\<15 mg), once daily at bedtime on Days 1-21 of each cycle (Cycles 1-n)","id":"OG000","title":"KRd-Elotuzumab"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all subjects who initiated Elo-KRd","reportingStatus":"POSTED","timeFrame":"From date of treatment start to date of death, or censored as described; assessed for approximately 5 years.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}